Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Return on Capital Employed of 48.09% for Q2 2026, up 1106.0% year-over-year from 3.99% in Q2 2025, and down 16.05% on a QoQ basis from 41.44% in Q1 2026.
Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Return on Capital Employed for 13 years, with the latest figure at 48.09% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 48.09%, up 1106.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 48.09% (up 1106.0% YoY), and the FY2025 annual result was 46.38%, up 839.0% from the prior year.
- Return on Capital Employed eased to 48.09% in Q2 2026, from 41.44% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 22.98% in Q2 2024 and troughed at 90.15% in Q2 2023.
- A 5-year average of 52.0% and a median of 48.59% in 2022 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2023, when Return on Capital Employed tumbled 4131 bps; it then jumped 6716 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 64.19% in 2022, then gained by 26 bps to 47.81% in 2023, then increased by 17 bps to 39.69% in 2024, then declined by 22 bps to 48.33% in 2025, then advanced by 1 bps to 48.09% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 48.09% in Q2 2026, 41.44% in Q1 2026, and 48.33% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -48.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.09% |
| Mar 31, 2026 | -41.44% |
| Dec 31, 2025 | -48.33% |
| Sep 30, 2025 | -65.69% |
| Jun 30, 2025 | -59.15% |
| Mar 31, 2025 | -51.80% |
| Dec 31, 2024 | -39.69% |
| Sep 30, 2024 | -30.22% |
| Jun 30, 2024 | -22.98% |
| Mar 31, 2024 | -24.64% |
| Dec 31, 2023 | -47.81% |
| Sep 30, 2023 | -76.06% |
| Jun 30, 2023 | -90.15% |
| Mar 31, 2023 | -76.33% |
| Dec 31, 2022 | -64.19% |
| Sep 30, 2022 | -56.64% |
| Jun 30, 2022 | -48.84% |
| Mar 31, 2022 | -43.90% |
| Dec 31, 2021 | -42.19% |
| Sep 30, 2021 | -37.34% |